Your browser is no longer supported. Please, upgrade your browser.
Settings
ADMS Adamas Pharmaceuticals, Inc. daily Stock Chart
ADMS [NASD]
Adamas Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.03 Insider Own1.10% Shs Outstand27.78M Perf Week-7.63%
Market Cap151.39M Forward P/E- EPS next Y-2.42 Insider Trans-0.93% Shs Float26.99M Perf Month49.32%
Income-111.00M PEG- EPS next Q-0.86 Inst Own72.00% Short Float8.82% Perf Quarter39.74%
Sales51.60M P/S2.93 EPS this Y-22.80% Inst Trans0.63% Short Ratio3.62 Perf Half Y-9.62%
Book/sh0.71 P/B7.68 EPS next Y37.20% ROA-52.90% Target Price11.94 Perf Year-37.07%
Cash/sh5.41 P/C1.01 EPS next 5Y39.30% ROE-205.30% 52W Range3.35 - 12.57 Perf YTD43.80%
Dividend- P/FCF- EPS past 5Y-29.00% ROI-55.00% 52W High-56.64% Beta1.76
Dividend %- Quick Ratio6.20 Sales past 5Y-13.70% Gross Margin95.20% 52W Low62.69% ATR0.46
Employees134 Current Ratio6.30 Sales Q/Q31.10% Oper. Margin- RSI (14)53.60 Volatility6.82% 7.72%
OptionableYes Debt/Eq6.35 EPS Q/Q18.30% Profit Margin- Rel Volume0.42 Prev Close6.01
ShortableYes LT Debt/Eq6.27 EarningsFeb 06 AMC Payout- Avg Volume657.97K Price5.45
Recom2.30 SMA2011.68% SMA502.54% SMA200-0.98% Volume278,139 Change-9.32%
Dec-18-19Reiterated H.C. Wainwright Buy $30 → $10
Sep-30-19Downgrade BofA/Merrill Neutral → Underperform $9 → $5
Sep-09-19Initiated Cantor Fitzgerald Neutral $8
Mar-05-19Downgrade Mizuho Neutral → Underperform $11 → $5
Nov-05-18Downgrade Mizuho Buy → Neutral
Oct-05-18Downgrade BofA/Merrill Buy → Neutral
Jul-16-18Initiated H.C. Wainwright Buy $45
Apr-04-18Initiated Leerink Partners Outperform $31
Mar-27-18Initiated BofA/Merrill Buy $39
Nov-29-17Initiated Northland Capital Outperform $70
Nov-08-17Reiterated Noble Financial Buy $33 → $48
Oct-30-17Initiated Evercore ISI Outperform $85
Sep-29-17Resumed Noble Financial Buy $33
Sep-19-17Reiterated Mizuho Buy $26 → $48
Aug-25-17Reiterated JMP Securities Mkt Outperform $29 → $33
Sep-08-16Reiterated Mizuho Buy $22 → $26
Jun-17-16Initiated Noble Financial Buy $25
Jun-16-16Upgrade Mizuho Neutral → Buy $22
May-12-16Reiterated Mizuho Neutral $17 → $16
Apr-28-16Reiterated Mizuho Neutral $14 → $17
Jan-26-20 07:55AM  Does Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Have A Particularly Volatile Share Price? Simply Wall St.
Jan-24-20 05:15PM  SHAREHOLDER ALERT: ADMS REAL EXC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE -9.32%
03:12PM  ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc. ACCESSWIRE
10:25AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, REAL and BZUN ACCESSWIRE
10:00AM  INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines GlobeNewswire
Jan-23-20 05:44PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
11:35AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, MMSI and PTLA ACCESSWIRE
11:00AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. GlobeNewswire
Jan-22-20 02:50PM  SHAREHOLDER ALERT: ADMS XYF BZUN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
02:00PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Firm GlobeNewswire
01:19PM  INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines GlobeNewswire
10:50AM  CLASS ACTION UPDATE for ADMS, BAX and MHK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
09:07AM  ADMS INVESTOR ALERT: Bernstein Liebhard LLP Encourages Investors With Losses in ADMS Exceeding 20K to Contact the Firm and Reminds Investors of a Filing Deadline in a Securities Class Action Against Adamas Pharmaceuticals, Inc ACCESSWIRE
Jan-21-20 07:05PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, BAX and MMSI ACCESSWIRE
05:50PM  ADMS INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action ADMS GlobeNewswire
11:55AM  CLASS ACTION UPDATE for ADMS, GRUB and XYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:00AM  DEADLINE ALERT for HEXO, XYF, BZUN, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Jan-17-20 04:55PM  SHAREHOLDER ALERT: ADMS FSCT EXC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
03:00PM  ADMS EQUITY NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.; Important Deadline in Case - ADMS ACCESSWIRE
10:20AM  CLASS ACTION UPDATE for ADMS, MMSI and BZUN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
09:56AM  INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines ACCESSWIRE
12:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
Jan-16-20 02:00PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, BZUN and EXC ACCESSWIRE
12:51PM  ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc. ACCESSWIRE
11:00AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. GlobeNewswire
10:45AM  SHAREHOLDER ALERT: ADMS PRU MHK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
Jan-15-20 06:55PM  ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
05:20PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, FCAU and BZUN ACCESSWIRE
04:32PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Firm GlobeNewswire
10:45AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, WSG and CGC ACCESSWIRE
Jan-14-20 10:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
07:50PM  SHAREHOLDER ALERT: ADMS FSCT HEXO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
06:15PM  ADMS INVESTOR ALERT: Bernstein Liebhard Encourages Investors With Losses in ADMS Exceeding 20K to Contact the Firm and Reminds Investors of a Filing Deadline in a Securities Class Action Against Adamas Pharmaceuticals, Inc ACCESSWIRE
04:45PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, AFI and PRU ACCESSWIRE
04:02PM  ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action ADMS GlobeNewswire
Jan-13-20 02:15PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, ET and EXC ACCESSWIRE +5.97%
02:00PM  NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:13PM  INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines GlobeNewswire
11:20AM  CLASS ACTION UPDATE for ADMS, WSG and XYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:00AM  DEADLINE ALERT for HEXO, XYF, ADMS, EXC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Jan-10-20 04:30PM  Adamas Announces New Employment Inducement Grant GlobeNewswire -6.49%
01:40PM  CLASS ACTION UPDATE for ADMS, FSCT and ET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:00AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. GlobeNewswire
10:30AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, REAL and BZUN ACCESSWIRE
10:00AM  INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines GlobeNewswire
Jan-09-20 03:30PM  CLASS ACTION UPDATE for ADMS, CGC and HEXO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE +8.61%
03:00PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Adamas Pharmaceuticals, Cintas, Correvio Pharma, and Exelon and Encourages Investors to Contact the Firm GlobeNewswire
10:45AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, ET and PRU ACCESSWIRE
09:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS PR Newswire
09:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS CNW Group
01:05AM  LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm PR Newswire
Jan-08-20 01:00PM  SHAREHOLDER ALERT: ADMS GDOT XYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE +22.84%
12:24PM  INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines GlobeNewswire
09:15AM  Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020 GlobeNewswire
Jan-06-20 04:50PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, XYF and EXC ACCESSWIRE
03:51PM  ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc. ACCESSWIRE
02:05PM  NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:50PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, REAL and XYF ACCESSWIRE
01:00PM  DEADLINE ALERT for YJ, UEPS, XYF, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:55AM  SHAREHOLDER ALERT: ADMS REAL TIGR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
09:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
Jan-05-20 10:35AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, REAL and FSCT ACCESSWIRE
Jan-04-20 11:00AM  ADMS INVESTOR ALERT: ROSEN, A TOP LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action ADMS GlobeNewswire
Jan-03-20 06:54PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
12:00PM  CLASS ACTION UPDATE for ADMS, WSG and ET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:30AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. GlobeNewswire
Jan-02-20 12:30PM  CLASS ACTION UPDATE for ADMS, GDOT and EXC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE +7.65%
12:00PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Net 1 UEPS Technologies, X Financial, Baozun, and Adamas Pharmaceuticals and Encourages Investors to Contact the Firm GlobeNewswire
09:00AM  Adamas Announces Settlement of Patent Litigation with Sandoz Inc. GlobeNewswire
Dec-31-19 02:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
Dec-30-19 12:55PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, ET and FCAU ACCESSWIRE
12:30PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. GlobeNewswire
Dec-29-19 10:45AM  CLASS ACTION UPDATE for ADMS, UNIT and BAX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
Dec-27-19 08:30PM  NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
07:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
12:05PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, TWTR and PLT ACCESSWIRE
11:47AM  ROSEN, NATIONAL TRIAL LAWYERS, Reminds Adamas Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action ADMS Business Wire
10:44AM  ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc. ACCESSWIRE
Dec-26-19 09:05PM  CLASS ACTION UPDATE for ADMS, AFI and XYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE +5.08%
08:20PM  SHAREHOLDER ALERT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Dec-24-19 02:50PM  SHAREHOLDER ALERT: ADMS GDOT BZUN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
02:20PM  INVESTOR ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, AZZ and AFI ACCESSWIRE
Dec-23-19 06:30PM  ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc. ACCESSWIRE
05:45PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, BAX and YJ ACCESSWIRE
05:44PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
02:10PM  NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:20PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, FCAU and XYF ACCESSWIRE
12:00PM  DEADLINE ALERT for UNIT, UEPS, XYF, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Dec-22-19 11:55AM  SHAREHOLDER ALERT: ADMS SEE TWTR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
Dec-21-19 09:22AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
Dec-20-19 05:30PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:15PM  CLASS ACTION UPDATE for ADMS, PLT and HEXO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
12:00PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. Business Wire
10:00AM  SHAREHOLDER ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020 GlobeNewswire
09:45AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, AZZ and ACB ACCESSWIRE
Dec-19-19 07:12PM  EQUITY ALERT: ROSEN LAW FIRM Announces Filing of Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. ADMS GlobeNewswire
05:50PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, TWTR and BZUN ACCESSWIRE
05:05PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:15PM  CLASS ACTION UPDATE for ADMS, GDOT and PRU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Prentiss Christopher BChief Financial OfficerJan 21Sale5.921,2697,51270,940Jan 23 05:33 PM
MERRIWEATHER ALFRED GChief Financial OfficerSep 20Sale6.911,58410,94548,019Sep 23 04:19 PM
MAHONEY DAVID LDirectorSep 17Option Exercise1.7633,33258,49857,153Sep 18 04:38 PM
Prentiss Christopher BChief Accounting OfficerJul 22Sale6.001,0826,49247,209Jul 23 06:06 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerJun 20Sale5.359405,02963,114Jun 21 05:38 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerMar 20Sale7.991,79214,31831,612Mar 21 04:39 PM
Went Gregory TChief Executive OfficerMar 20Sale7.996,31950,489176,291Mar 21 04:37 PM
MERRIWEATHER ALFRED GChief Financial OfficerMar 20Sale7.998576,84724,603Mar 21 04:47 PM
Patni RajivChief Medical OfficerMar 20Sale8.002,37418,99219,141Mar 21 04:45 PM
Prentiss Christopher BChief Accounting OfficerMar 20Sale8.001,1859,48029,541Mar 21 04:43 PM